-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Preventing atherosclerosis -- the underlying cause of heart disease -- means scientists need to understand how immune cells drive arterial inflammati.
The difficulty is that T cells involved in atherosclerosis are very rare and hard to find in the blo.
But T cells cannot hide forev.
Apolipoprotein B (APOB) is the main protein component of low density lipoprotein (LDL) or "bad" cholester.
Ley and his colleagues found that T cells targeting APOB may promote the further development of inflammation and atheroscleros.
"Apolipoprotein B-specific T cells become more aggressive at the onset of the disease," Ley sa.
The new study is the first to provide a highly detailed description of the T cells involved in atheroscleros.
In collaboration with scientists at the Albert Einstein College of Medicine, the LJI team carefully analyzed more than 12,000 T cells from these patients using two cutting-edge technologies, single-cell RNA sequencing and T-cell receptor sequenci.
When they zoomed in further, the researchers found that APOB-targeting T cells resembled a type of T cells called regulatory T cells (Treg), which normally regulate inflammati.
This research is good news for future treatments for heart disea.
In the future, Ley plans to study a broader patient population, including men with atheroscleros.
Courtesy of La Jolla Institute for Immunology
